Alexandra MacLean - Sep 23, 2024 Form 4 Insider Report for AVENUE THERAPEUTICS, INC. (ATXI)

Role: Chief Executive Officer, Director
Signature: /s/ David Jin, Attorney-in-Fact
Stock symbol: ATXI
Transactions as of: Sep 23, 2024
Transactions value $: $0
Form type: 4
Date filed: 9/25/2024, 04:55 PM
Previous filing: Jul 3, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ATXI	COMMON STOCK, PAR VALUE $0.0001	Award	$0	+170K		$0.00	170K	Sep 23, 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents an award of 170,000 restricted stock units which will vest in equal installments at September 30, 2024, December 31, 2024, September 23, 2025, and September 23, 2026. The shares underlying the restricted stock units will not be settled until the earlier of the tenth business day of January of the year following certain terminations of service of the Reporting Person from the Issuer and Change in Control events (as defined in the Avenue Therapeutics, Inc. 2015 Incentive Plan); the amount will be distributed in the form of the Issuer's common stock.

Content

Represents an award of 170,000 restricted stock units which will vest in equal installments at September 30, 2024, December 31, 2024, September 23, 2025, and September 23, 2026. The shares underlying the restricted stock units will not be settled until the earlier of the tenth business day of January of the year following certain terminations of service of the Reporting Person from the Issuer and Change in Control events (as defined in the Avenue Therapeutics, Inc. 2015 Incentive Plan); the amount will be distributed in the form of the Issuer's common stock.